<DOC>
	<DOC>NCT00301457</DOC>
	<brief_summary>The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen</brief_summary>
	<brief_title>Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of locoregional recurrences or distant metastasis Previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen. Previous history of invasive breast cancer within the last 10 years, other then the breast cancer that is currently treated with tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hormone Sensitive Primary Breast Cancer</keyword>
	<keyword>Adjuvant Treatment</keyword>
	<keyword>Aromatase Inhibitor</keyword>
</DOC>